CA2603189A1 - Formulations de depot injectables et procedes destines a assurer une liberation prolongee de medicaments peu solubles comprenant des nanoparticules - Google Patents

Formulations de depot injectables et procedes destines a assurer une liberation prolongee de medicaments peu solubles comprenant des nanoparticules Download PDF

Info

Publication number
CA2603189A1
CA2603189A1 CA002603189A CA2603189A CA2603189A1 CA 2603189 A1 CA2603189 A1 CA 2603189A1 CA 002603189 A CA002603189 A CA 002603189A CA 2603189 A CA2603189 A CA 2603189A CA 2603189 A1 CA2603189 A1 CA 2603189A1
Authority
CA
Canada
Prior art keywords
formulation
compound
weight
particle size
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002603189A
Other languages
English (en)
Inventor
Jaymin Chandrakant Shah
Parag Suresh Shah
Dawn Renee Wagner
Peter Wisniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2603189A1 publication Critical patent/CA2603189A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002603189A 2005-04-13 2006-04-10 Formulations de depot injectables et procedes destines a assurer une liberation prolongee de medicaments peu solubles comprenant des nanoparticules Abandoned CA2603189A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67112305P 2005-04-13 2005-04-13
US60/671,123 2005-04-13
PCT/IB2006/001011 WO2006109177A1 (fr) 2005-04-13 2006-04-10 Formulations de depot injectables et procedes destines a assurer une liberation prolongee de medicaments peu solubles comprenant des nanoparticules

Publications (1)

Publication Number Publication Date
CA2603189A1 true CA2603189A1 (fr) 2006-10-19

Family

ID=36754516

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002603189A Abandoned CA2603189A1 (fr) 2005-04-13 2006-04-10 Formulations de depot injectables et procedes destines a assurer une liberation prolongee de medicaments peu solubles comprenant des nanoparticules

Country Status (4)

Country Link
EP (1) EP1874267A1 (fr)
JP (1) JP2009533314A (fr)
CA (1) CA2603189A1 (fr)
WO (1) WO2006109177A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294970A1 (en) * 2008-09-19 2014-10-02 Alcon Research, Ltd. Stabilized pharmaceutical sub-micron suspensions and methods of forming same

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7980753B2 (en) 1998-04-16 2011-07-19 Air Liquide Electronics U.S. Lp Systems and methods for managing fluids in a processing environment using a liquid ring pump and reclamation system
EP2310009B1 (fr) * 2008-07-24 2017-12-20 University Of Houston Formulations parentérales et orales de benzimidazoles
KR101275413B1 (ko) * 2008-12-29 2013-06-18 주식회사 삼양바이오팜 동결건조제형의 약제학적 조성물 및 그 제조방법
EP2538929A4 (fr) 2010-02-25 2014-07-09 Univ Johns Hopkins Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
CA2853470A1 (fr) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Procede de preparation de nano-suspensions
EP2825206A1 (fr) 2012-03-16 2015-01-21 The Johns Hopkins University Formulations à libération contrôlée pour l'administration d'inhibiteurs du hif-1
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN104814926A (zh) * 2015-04-08 2015-08-05 中国药科大学 一种鲁拉西酮纳米混悬剂及其制备方法
AR106085A1 (es) * 2015-09-21 2017-12-13 Teva Pharmaceuticals Int Gmbh Formulaciones de olanzapina de liberación sostenida
EP3570833A4 (fr) 2017-01-20 2020-08-05 Warsaw Orthopedic, Inc. Compositions anesthésiques et procédés comprenant des composés d'imidazoline
CA3057438A1 (fr) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Formulations d'olanzapine a liberation prolongee
BR112021002675A2 (pt) * 2018-08-14 2021-05-11 Jiangsu Hengrui Medicine Co., Ltd. composições farmacêuticas, métodos para preparar as referidas composições e uso das mesmas
CN111904947A (zh) * 2019-05-07 2020-11-10 江苏恒瑞医药股份有限公司 一种注射用药物组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
EP1269994A3 (fr) * 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
EP2263650A3 (fr) * 2002-04-12 2013-12-25 Alkermes Pharma Ireland Limited Formulations de mégestrol nanoparticulaire
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294970A1 (en) * 2008-09-19 2014-10-02 Alcon Research, Ltd. Stabilized pharmaceutical sub-micron suspensions and methods of forming same

Also Published As

Publication number Publication date
JP2009533314A (ja) 2009-09-17
EP1874267A1 (fr) 2008-01-09
WO2006109177A1 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
US20080166411A1 (en) Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
CA2603189A1 (fr) Formulations de depot injectables et procedes destines a assurer une liberation prolongee de medicaments peu solubles comprenant des nanoparticules
RU2407529C2 (ru) Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
US20080305161A1 (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP2021008521A (ja) アビラテロン酢酸エステル製剤
EP3434261B1 (fr) Formules à méloxicam nanoparticulaire
US20040156872A1 (en) Novel nimesulide compositions
CN101232870A (zh) 纳米微粒甲磺酸伊马替尼制剂
EP2279727A2 (fr) Formulations nanoparticulaires d'aripiprazole
CN101175481A (zh) 纳米颗粒免疫抑制化合物的可注射的组合物
KR20170070025A (ko) 아비라테론 아세테이트 제제 및 사용 방법
CN103998037A (zh) 对高熔点疏水性化合物具有改进的生物利用度的药物组合物
FR2945950A1 (fr) Compositions de nanoparticules anticancereuses et procedes pour les preparer
SG175768A1 (en) A novel formulation of meloxicam
EP1923051A1 (fr) Microparticule de substance à peine soluble ayant un matériau de base entérique adsorbé à la surface de la substance
JP5759464B2 (ja) オキサリプラチンのナノ粒子及びその製造方法
EP1684725A1 (fr) Nouvelles compositions de nimesulide
CN102772365A (zh) 4-(4-(3-三氟甲基)苯甲酰胺基苯氧基)-2-(甲基氨甲酰基)吡啶纳米混悬剂及其制法和应用
CN113018268A (zh) 一种注射用德拉沙星葡甲胺冻干制剂及其制备方法
OA18169A (en) Abiraterone acetate formulation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130410